Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Advances in Heart Failure

Author(s): Spyridon Deftereos, Dimitrios A. Vrachatis and Konstantinos A. Papathanasiou

Volume 29, Issue 7, 2023

Published on: 29 March, 2023

Page: [i - i] Pages: 1

DOI: 10.2174/138161282907230329124348

Price: $65

« Previous
[1]
Vrachatis DA, Papathanasiou KA, Giotaki SG, et al. Advances in the management of heart fail-ure with reduced ejection fraction; The role of SGLT2is, ARNI, Myotropes, Vericiguat, and anti-inflammatory agents: A mini-review. Curr Pharm Design 2023; 29(7): 509-18.
[http://dx.doi.org/10.2174/1381612829666230316142450]
[2]
Gitto M, Villaschi A, Federici M, Condorelli G, Stefanini GG. The emerging role of sodium-glucose cotransporter 2 inhibitors in heart failure. Curr Pharm Des 2023; 29(7): 481-93.
[http://dx.doi.org/10.2174/1381612829666230217143324]
[3]
Giannopoulos G, Kousta M, Anagnostopoulos I, et al. Advances in heart failure with preserved ejec-tion fraction management - the role of sacubitril-valsartan, pirfenidone, spironolactone and empagli-flozin: is success a series of small victories?. Curr Pharm Design 2023; 29(7): 502-9.
[4]
Yin Ong JS, Lin W, Yeo TJ. The role of exercise-based cardiac rehabilitation in heart failure. Curr Pharm Des 2023; 29(7): 494-502.
[http://dx.doi.org/10.2174/1381612829666230217145100]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy